AGC Biologics’ Heidelberg Facility to Manufacture Drug Substance for Phase II Trials of Valneva’s Four-Valent Shigella Vaccine Candidate AGC Biologics, a global contract development and manufacturing organization (CDMO), announced a new partnership with specialty vaccine company Valneva SE (Nasdaq: VALN;…
Simulations Plus and Polish Academy Scientists Validate AI-Powered Drug Design Models in Breakthrough Discovery Targeting Inflammation and Immune Regulation Simulations Plus, Inc. (Nasdaq: SLP), a prominent developer of modeling and simulation software for the biopharmaceutical industry, in collaboration with the…
Bio-Rad Laboratories Appoints Rajat Mehta as Executive Vice President of Global Commercial Operations, Marking a New Era in Strategic Leadership Herculean succession marks leadership transition following the retirement of Mike Crowley, closing a pivotal chapter in Bio-Rad’s growth story while…
Biocytogen Elevates Preclinical Research Services and Global Engagement with Strategic Platform Upgrade and Website Relaunch Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKEX: 02315), a pioneering force in the biotechnology sector known for its cutting-edge antibody discovery and preclinical services, has taken…
DiaMedica Therapeutics Secures $30.1 Million in Oversubscribed Private Placement to Bolster Advancement of Neurological and Maternal Health Pipeline Proceeds strengthen company’s financial runway as it targets innovative treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke DiaMedica Therapeutics Inc.…
Crossbow Therapeutics Advances Second TCR-Mimetic Cancer Therapy Candidate, CBX-663, Targeting TERT Across Broad Range of Tumors Crossbow Therapeutics, Inc., a biotechnology company pioneering a new class of T-cell receptor (TCR)-mimetic antibody therapeutics through its proprietary T-Bolt™ platform, has announced the…
Lantern Pharma Achieves Landmark Complete Response in Heavily Pretreated Lymphoma Patient, Validating AI-Driven Precision Oncology Strategy Lantern Pharma’s LP-284 demonstrates transformative clinical potential in one of the most difficult-to-treat blood cancers, marking a milestone for AI-guided drug development and synthetic…
ReAlta Life Sciences Publishes Preclinical Data Showing RLS-0071 Reduces Brain Inflammation in Neonatal Hypoxic-Ischemic Encephalopathy Model ReAlta Life Sciences, Inc., a clinical-stage biopharmaceutical company advancing therapies that rebalance the body’s inflammatory response, has announced the publication of new preclinical findings…
Sarepta Therapeutics Responds to FDA’s Voluntary Halt Request for ELEVIDYS Shipments and Clarifies Gene Therapy Safety Concerns Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leading biotechnology company at the forefront of developing precision genetic medicines for rare neuromuscular diseases, issued a…
Wedgewood Expands and Evolves Its Veterinary Advisory Committee with the Launch of Two New Councils to Strengthen Clinical Collaboration and Strategic Insight Wedgewood, a long-standing leader in veterinary pharmacy and a trusted partner to veterinary professionals across the United States,…
Merck and SpringWorks Secure Conditional EU Approval for EZMEKLY®, the First Therapy for NF1-Associated Plexiform Neurofibromas in Both Adults and Children Merck, a global leader in science and technology, announced that the European Commission (EC) has granted conditional marketing authorization…
Genascence Secures RMAT Designation for Groundbreaking Gene Therapy GNSC-001 in Knee Osteoarthritis, Signaling a Major Step Forward in Regenerative Medicine Genascence Corporation, a clinical-stage biotechnology company pioneering gene therapy solutions for chronic musculoskeletal diseases, announced that the U.S. Food and…